vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients

被引：0
|
作者：
Marino, M. [1 ]
Domenis, R. [2 ]
Biribin, L. [1 ]
Cifu, A. [2 ]
Navarria, L. [1 ]
Scardino, G. [1 ]
Fabris, M. [2 ]
机构：
[1] Azienda Sanit Univ Integrata Udine, Dept Gastroenterol, Udine, Italy
[2] Azienda Sanit Univ Integrata Udine, Ist Patol Clin, Udine, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P588
引用
收藏
页码：S492 / S492
页数：1
相关论文
共 50 条
  • [11] LOW INFLIXIMAB TROUGH LEVELS AT WEEK 6 AND 14 IN AN ASIAN INFLAMMATORY BOWEL DISEASE COHORT ARE NOT ASSOCIATED WITH POORER CLINICAL OUTCOME
    Lim, Chong Teik
    Koh, Samantha J.
    Tay, Shu Wen
    Salazar, Ennaliza
    Chan, Pak Wo
    Tan, Malcolm
    GASTROENTEROLOGY, 2022, 162 (07) : S1095 - S1096
  • [12] HIGHER VEDOLIZUMAB TROUGH LEVELS ASSOCIATED WITH REMISSION IN INFLAMMATORY BOWEL DISEASE (IBD) DURING MAINTENANCE THERAPY
    Ungaro, Ryan C.
    Jossen, Jacqueline
    Phan, Becky L.
    Chefitz, Ezra
    Sehgal, Priya
    Jain, Anjali
    Naik, Snehal
    Dubinsky, Marla
    GASTROENTEROLOGY, 2017, 152 (05) : S384 - S385
  • [13] Serum vedolizumab assay at week 6 predicts sustained clinical remission and lack of recourse to optimisation in inflammatory bowel disease
    Williet, N.
    Paul, S.
    Del Tedesco, E.
    Phelip, J. M.
    Roblin, X.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S421 - S421
  • [14] Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease
    Courbette, Olivier
    Aupiais, Camille
    Viala, Jerome
    Hugot, Jean-Pierre
    Roblin, Xavier
    Candon, Sophie
    Louveau, Baptiste
    Chatenoud, Lucienne
    Martinez-Vinson, Christine
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 70 (03): : 310 - 317
  • [15] Clinical outcomes of vedolizumab withdrawal in inflammatory bowel disease for patients in histological remission
    Blad, William
    Whitley, Lisa
    Harrow, Paul
    GUT, 2023, 72 (SUPPL_2) : A87 - A88
  • [16] Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
    O'Connell, J.
    McDonagh, P.
    Hazel, K.
    Fiona, J.
    Dunne, C.
    Farrell, R.
    Harewood, G.
    Hartery, K.
    Kelly, O.
    MacCarthy, F.
    McKiernan, S.
    Murray, F.
    O'Morain, C.
    Aoibhlinn, O.
    Kevans, D.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S473 - S473
  • [17] MAINTENANCE LEVELS OF VEDOLIZUMAB DO NOT CORRELATE WITH CLINICAL REMISSION IN IBD PATIENTS
    Tessolini, Jenna M.
    Bajaj, Girish
    Zezos, Petros
    O'Connell, Jim W.
    Huang, Vivian
    Croitoru, Kenneth
    Steinhart, A. Hillary
    Kelly, Orlaith
    O'Toole, Aoibhlinn
    Kevans, David
    Silverberg, Mark S.
    GASTROENTEROLOGY, 2019, 156 (06) : S1140 - S1140
  • [18] EARLY VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL RESPONSE IN A "REAL WORLD" PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
    Bonthala, Nirupama
    Morganstern, Bradley
    Mengesha, Emebet
    Landers, Carol
    Mould, Diane R.
    Li, Dalin
    Vasiliauskas, Eric
    Targan, Stephan R.
    McGovern, Dermot P. B.
    Melmed, Gil
    GASTROENTEROLOGY, 2020, 158 (06) : S465 - S466
  • [19] VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang
    Raffals, Laura
    Tremaine, William J.
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S62 - S63
  • [20] Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease
    Yacoub, W.
    Williet, N.
    Pouillon, L.
    Di-Bernado, T.
    Bittencourt, M. De Carvalho
    Nancey, S.
    Lopez, A.
    Paul, S.
    Zallot, C.
    Roblin, X.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S334 - S334
12345